Gornitzky represented the underwriters, led by Goldman Sachs, J.P. Morgan and Jefferies, in the USD 172.5 million follow-on offering of UroGen Pharma Ltd. on the NASDAQ Global Market.
UroGen Pharma is a clinical-stage bio-pharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. Goldman Sachs & Co. LLC, J.P. Morgan and Jefferies acted as joint book-running managers for the offering. Oppenheimer & Co. acted as lead manager for the offering.
The underwriters were represented by Chaim Friedland (Partner), Ari Fried (Partner), Neta Peled (Associate) and Nir Knoll (Associate).